北京若生智能科技有限公司
Drug Database
EP

epidermal growth factor receptor (EGFR pharmDx / EGFR pharmDx Kit)

✓ Approved

Dako · EGFR · 辅助诊断

什么是 epidermal growth factor receptor？

epidermal growth factor receptor 是一种辅助诊断，由Dako研发。该药已获批，用于治疗相关适应症，给药途径：Others。

药物档案

商品名EGFR pharmDx, EGFR pharmDx Kit
公司Dako
药物类别辅助诊断
分子靶点EGFR
给药途径Others
状态Approved
来源： ClinicalTrials.gov, Dako

作用机制

分子靶点

epidermal growth factor receptor 作用于 1 个分子靶点：

EGFRepidermal growth factor receptor (ERBB1, NNCIS)
需要更深入的分析？Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

epidermal growth factor receptor 针对 1 个适应症，涉及 1 个治疗领域。

治疗领域疾病/病症分期
Neoplasms benign, malignant and unspecified (incl cysts and polyps)Uterine cancer✓ Approved

相关研究文献

PubMedFrontiers in molecular biosciences2026-10-26

Copper complexes in the triple-negative breast cancer landscape: advances and opportunities.

Lima Paula Marynella Alves Pereira PMAP, de Matos André Carlos Pereira ACP, Guimarães Gabriela da Silva GDS, Barbosa Laryssa Aparecida Sales LAS et al.

Triple-negative breast cancer (TNBC) is a subset of mammary tumors with heterogeneous biology, lacking estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 (HER2). Patients generally exhibit an aggressive course, less favorable disease-specific outcomes, and a higher propensity for early recurrence, with chemotherapy remaining the primary systemic treatment eligible for all patients. In this sense, efforts are urgent to identify new effective compounds, aiming to increase disease-free and overall survival. Copper complexes have emerged as promising in oncology by regulating redox balance and modulating hallmarks such as proliferation, apoptosis, epithelial-mesenchymal transition, and angiogenesis. Furthermore, complexes containing copper tend to have low adverse effects. In TNBC, copper compounds may represent at least one component of a multi-action management strategy, being potentially effective against these tumors. The focus of this review is to provide information on TNBC biology and the role of copper in its signaling pathways, addressing the current copper complexes that have been explored to improve treatment.

PMID 42928858
阅读全文 →
PubMedCurrent oncology (Toronto, Ont.)2026-10-26

Real-World Treatment Utilization and Patterns of Adjuvant Olaparib for Early-Stage Breast Cancer: Insights from the Komodo Research Database.

Batalini Felipe F, Li Qixin Q, Hayes Jennifer F JF, Mishkin Kathryn K et al.

Background and Objectives: As adjuvant treatment for human epidermal growth factor receptor 2 (HER2)-negative early-stage breast cancer (eBC) evolves, real-world data should inform olaparib utilization, sequencing, and combination patterns in clinical practice. Methods: Using Komodo US claims data (1 January 2019-31 December 2023), we retrospectively analyzed HER2-negative eBC patients on adjuvant olaparib. Continuous insurance for 12 months pre- and ≥30 days post-index date (first olaparib prescription), with follow-up through disenrollment or study end, was required. Outcomes, including time on therapy (Kaplan-Meier median persistence), adherence (proportion of days covered), dose reduction, and combination patterns, were stratified by claims-derived hormone-receptor-positive (HR+) and triple-negative BC (TNBC) status. Results: Among 176 olaparib-treated patients (median age, 44 years), the median (95% CI) time on therapy was 11.0 (9.2, 12.2) months; 27.3% (n = 48) discontinued before 12 months without re-initiating, 19.9% experienced a dose reduction, and median adherence was 90%. Olaparib was combined with other therapies in 48.3% (n = 85) (29.6% [32/108] of TNBC and 77.9% [53/68] of HR+ patients), most often with immunotherapy in TNBC (81.3%, n = 26) and endocrine therapy in HR+ (88.7%, n = 47). Conclusions: Real-world data suggest favorable persistence and dosing patterns with adjuvant olaparib. Future research should prioritize olaparib combination regimen safety and effectiveness.

PMID 42930156
阅读全文 →
PubMedCurrent oncology (Toronto, Ont.)2026-10-26

Triple Genetic Alterations (EGFR Mutation, ALK Fusion, and MET Polysomy) in Gynecological Metastasis of Lung Adenocarcinoma Patient with Acquired Resistance to Furmonertinib: A Case Report.

Jiang Qinglong Q, Sun Rui R, Xu Haiyan H, Wang Yanfeng Y

For advanced non-small cell lung cancer (NSCLC) with epidermal growth factor receptor (EGFR) mutations, targeted therapy is the standard first-line treatment, but acquired resistance and disease progression are inevitable. Identification of resistance mechanisms is crucial for guiding subsequent anti-tumor therapy. We report a 57-year-old female patient with advanced lung adenocarcinoma harboring an EGFR exon 21 L858R mutation. The patient experienced disease progression with rare gynecological metastasis after 16 months of first-line furmonertinib therapy. Next-generation sequencing (NGS) of the uterine metastatic lesion identified concurrence of EGFR mutation and ALK fusion, while fluorescence in situ hybridization (FISH) confirmed MET polysomy. The patient exhibited intolerance to the combination therapy of glumetinib plus furmonertinib. Subsequently, the patient received a combination of furmonertinib and the ALK-TKI ensartinib, which was assessed as a partial response (PR) at the first restaging evaluation (1 month after treatment initiation), with favorable safety and tolerability. Secondary ALK fusion may represent a rare but clinically meaningful resistance mechanism in EGFR-mutant NSCLC. Furthermore, while gynecological metastasis from lung cancer is uncommon, clinicians should be alert to this possibility in patients presenting with relevant symptoms, with pelvic examination conducted as needed.

PMID 42930180
阅读全文 →
PubMedCurrent oncology (Toronto, Ont.)2026-10-26

Risk Stratification and Factors Associated with Heart Failure Hospitalization During Osimertinib Therapy.

Sugimoto Tomoya T, Noguchi Yoshihiro Y, Masuda Rikuto R, Tani Sorami S et al.

Osimertinib is the standard of care for epidermal growth factor receptor mutation-positive non-small cell lung cancer, but heart failure hospitalization (HFH) remains a concern, and no practical tool exists to stratify HFH risk during therapy. In this retrospective cohort study using a Japanese claims database, 5802 patients newly initiating osimertinib were followed for HFH during treatment. Baseline predictors assessed before the index date were selected by 10-fold cross-validated least absolute shrinkage and selection operator (LASSO) logistic regression and internally validated by bootstrapping (B = 500), repeating predictor selection in each resample. Cumulative incidence functions and Fine-Gray models treated death as a competing event; cause-specific Cox models served as sensitivity analyses. HFH occurred in 169 patients (2.9%) during a median on-treatment follow-up of 9.3 months, with 268 competing deaths. LASSO retained seven predictors. The apparent concordance index (C-index) was 0.731 (95% confidence interval, 0.691-0.771) and the optimism-corrected C-index 0.718. Observed incidence increased 10.2-fold across predicted-risk deciles (1.03-10.50%). Fine-Gray and Cox estimates closely matched the logistic model. Baseline cardiovascular vulnerability stratifies HFH risk during osimertinib therapy. The nomogram, not externally validated, is best used as a screening aid to identify patients who may benefit from intensified cardiovascular monitoring.

PMID 42930153
阅读全文 →
PubMedAntibodies (Basel, Switzerland)2026-10-26

Antibody-Related Mechanisms in Ocular Diseases: Autoimmunity, Malignancy, and Therapeutic Targeting.

Xiao Yehan Y, Zou Yaru Y, Yang Mingming M, Gu Wendong W et al.

Antibodies in ocular disease have heterogeneous biological meanings: they may act as direct pathogenic effectors, systemic diagnostic biomarkers, indicators of B-cell clonality, or therapeutic agents. This distinction is particularly important in the eye, where immune privilege and the blood-ocular barrier restrict tissue access, whereas inflammation may permit entry of immunoglobulins, complement, and immune cells or support local humoral responses. This narrative review integrates antibody and B-cell biology across autoimmune and paraneoplastic retinopathies, aquaporin-4-immunoglobulin G-positive neuromyelitis optica spectrum disorder, myelin oligodendrocyte glycoprotein antibody-associated disease, ocular mucous membrane pemphigoid, ocular myasthenia gravis, thyroid eye disease, systemic autoimmune and fibroinflammatory disorders with ocular involvement, and B-cell malignancies including vitreoretinal and ocular adnexal lymphoma. We distinguish the evidence for direct antibody pathogenicity from disease association and emphasize that a positive result is interpretable only in relation to the ocular phenotype, assay platform, titer, specimen compartment, and orthogonal confirmation. Serum testing, ocular-fluid analysis, electrophysiology, multimodal imaging, cytology, histopathology, immunophenotyping, immunoglobulin clonality, and molecular testing have complementary roles. Therapeutic strategies include B-cell or B-lineage depletion, complement inhibition, cytokine- or receptor-directed monoclonal antibodies, insulin-like growth factor-1 receptor blockade, and emerging FcRn- or plasma-cell-directed approaches; however, regulatory status and ocular-specific evidence vary substantially among diseases. A mechanistically stratified framework may reduce overdiagnosis, improve recognition of malignant masquerade syndromes, and support more precise selection of targeted therapy.

PMID 42930036
阅读全文 →
PubMedCurrent oncology (Toronto, Ont.)2026-10-26

Societal and Healthcare Costs of Post-IDFS Events Following Adjuvant Ribociclib Plus an Aromatase Inhibitor (AI) Versus AI Alone in Pre- and Postmenopausal Women with Early HR+/HER2- Breast Cancer in Canada.

Soliman Dina D, Brezden-Masley Christine C, Sehdev Sandeep S, Sabater Anaya Natalia N et al.

Recent advancements in early breast cancer (EBC) for high-risk populations have significantly improved invasive disease-free survival (IDFS). While cost-effectiveness has been assessed, the broader societal impact of improved IDFS remains unstudied. A non-homogeneous semi-Markov model was developed to estimate total healthcare and societal costs after first-line treatment with ribociclib plus an aromatase inhibitor (AI) or, alternatively, AI alone in patients with hormone-receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) EBC. Using an incidence-based approach, the model calculated total expected annual societal costs of disease-related events after cessation of adjuvant treatment with ribociclib plus AI or AI alone for HR+/HER2- EBC. The model includes five states: IDFS, non-metastatic recurrence (NMR), distant recurrence (DR), secondary primary malignancy (SPM) and death, with a one-year cycle length, and a new cohort entering each year. Health state transition probabilities are based on a previously published cost-effectiveness model (CEM). Costs are tallied only after IDFS (after cessation of adjuvant treatment) and include direct costs of medical care as well as indirect costs related to employment, productivity, and wage loss. At the 4-year NATALEE data cut-off (April 2024), ribociclib plus AI reduced the risk of an IDFS event by 28.5% versus AI alone (HR 0.715), corresponding in the model to 23% fewer non-fatal events (NMR, DR, and SPM), 18% lower mortality, 23% lower total direct costs (-$957,471,465), and 24% lower indirect costs (-$448,542,692) from the period of cessation of adjuvant therapy until death. Healthcare savings were driven primarily by fewer distant recurrences and deaths, while societal savings were largely due to reduced caregiver costs. Treatments that reduce disease recurrence and mortality can significantly lower societal costs and alleviate burden on the healthcare system.

PMID 42930162
阅读全文 →

注册免费账户还可查看另外 9996 篇文献

免费注册查看全部文献 →

了解更多epidermal growth factor receptor